A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Public ClinicalTrials.gov record NCT02316717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
Study identification
- NCT ID
- NCT02316717
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Oct 29, 2017
- Completion
- Oct 29, 2017
- Last update posted
- Feb 20, 2020
2014 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| eStudySite | Chula Vista | California | 91911 | — |
| University of California San Diego | San Diego | California | 92103 | — |
| Quest Clinical Research | San Francisco | California | 94115 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| University of Florida Hepatology Research at CTRB | Gainesville | Florida | 32610 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Kansas City Research Institute | Kansas City | Missouri | 64131 | — |
| Duke Liver Centre | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Baylor St Lukes Medical Centre | Houston | Texas | 77030 | — |
| Brooke Army Medical Centre | Houston | Texas | 78234 | — |
| Pinnacle Clinical Research | Live Oak | Texas | 78233 | — |
| University of Virginia Medical Centre | Charlottesville | Virginia | 22908 | — |
| Mary Immaculate Hospital | Newport News | Virginia | 23602 | — |
| Bon Secours St Marys Hospital | Richmond | Virginia | 23226 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
| Swedish Medical Centre | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02316717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2020 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02316717 live on ClinicalTrials.gov.